When was Ardigen founded?

Ardigen was founded in 2015 and raised its 1st funding round 5 years after it was founded.

Where is Ardigen located?

Ardigen is headquartered in Krakow, Poland. It is registered at UL. PODOLE 76 30-394 KRAKÓW POLSKA.

How many employees does Ardigen have?

As of Sep 30, 2026, the latest employee count at Ardigen is 134.

Is Ardigen a funded company?

Ardigen is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 23, 2020.

When was the latest funding round of Ardigen?

Ardigen's latest funding was a $***** Grant (prize money) round on Oct 25, 2021, with participation from 1 investor.

Where does Ardigen rank among its competitors?

Ardigen ranks 207th amongst 2252 active competitors, of which 506 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Ardigen?

Ardigen's top competitors include Strand Life Sciences, Antheia and Cellworks. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Ardigen - 2026 Company Profile, Funding & Competitors

Ardigen is a funded company based in Krakow (Poland), founded in 2015. It operates as a Provider of AI-driven solutions for drug discovery and clinical development. Ardigen has raised an undisclosed amount in funding. The company has 2252 active competitors, including 506 funded and 330 that have exited. Its top competitors include companies like Strand Life Sciences, Antheia and Cellworks.

Company Details

Provider of AI-driven solutions for drug discovery and clinical development. The company offers services spanning target identification, small molecule design, biologics development, and clinical data analysis. It delivers bioinformatics, data management, and software engineering to streamline research. The company provides custom algorithms and models for accurate predictions in drug programs.

Website: ardigen.com
Social
Email ID: *****@ardigen.com
Phone Number: +48 **********
Registered Address: UL. PODOLE 76 30-394 KRAKÓW POLSKA

Key Metrics

Founded Year

2015

Location

Krakow, Poland

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Oct 25, 2021, $*****

Investors

NCBR

Ranked

207^th among 2252 active competitors

Employee Count

134 as on Sep 30, 2026

Similar Companies

OpenEvidence & 5862 more

View Ardigen's full profile

Ardigen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ARDIGEN SPÓŁKA AKCYJNA CIN: 0000585459 , Poland, Active	Nov 12, 2015	-	-

Ardigen has raised funding over 2 rounds. Its first funding round was on Sep 23, 2020. Its latest funding round was a Grant (prize money) round on Oct 25, 2021 for $*****. 1 investor participated in its latest round. Ardigen has 1 institutional investor.

Here is the list of recent funding rounds of Ardigen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 25, 2021	2142065	Grant (prize money)	2030444	5977087	9404452	9087858
Sep 23, 2020	8924981	Grant (prize money)	1865438	2574913	5100936	NCBR

Access funding benchmarks and valuations. Sign up today!

View details of Ardigen's funding rounds and investors

Ardigen's employee count trend

Ardigen has 134 employees as of Sep 26. Here is Ardigen's employee count trend over the years:

Uncover Ardigen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ardigen include Strand Life Sciences, Antheia and Cellworks. Here is the list of Top 10 competitors of Ardigen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Strand Life Sciences 2000, Bengaluru (India), Acquired	Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery	$34.9M	Biomark Capital, WestBridge Capital & 92 others	74/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Cellworks 2005, San Jose (United States), Series B	Developer of a biosimulation platform	$16.5M	Bering Capital, Artiman & 3 others	66/100
4th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
7th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
8th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
9th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
10th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	62/100
207th	Ardigen 2015, Krakow (Poland), Funding Raised	Provider of AI-driven solutions for drug discovery and clinical development	-	NCBR	41/100